Real‐world outcomes of neoadjuvant chemoimmunotherapy in patients with nonsmall cell lung cancer: Predictors of surgery, pathologic complete response, and event‐free survival
Observational analysis assessed predictors of surgery and pathologic complete response in NSCLC patients, indicating varying outcomes based on molecular markers.
Key Points
The study found that positive PD-L1 expression significantly increased the likelihood of achieving a pathologic complete response.
Older patients aged over 72 years were less likely to proceed to surgical resection compared to younger patients.
Among 115 analyzed patients, 78% underwent surgical resection, with notable rates of pathologic responses after neoadjuvant treatment.
The median event-free survival was not reached, suggesting further investigation is warranted to understand long-term outcomes.